Among the 36 patients with PTCL and CTCL, objective response rate based on the independent review was 36% (41% in PTCL, and 31% in CTCL). The median progression-free survival was 3.1 months (2.1 months in PTCL and 4.2 months in CTCL). Our results indicated that a 9 µg/kg/day dose of E7777 shows efficacy and a manageable safety profile in Japanese patients with relapsed or refractory PTCL and CTCL, with clinical activity observed across the range of CD25 expression.